EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study

Floris Bosch iD, Erzsébet Horváth-Puhó iD, Suzanne C Cannegieter iD, Nick van Es iD, Henrik T Sørensen iD

PLOS Medicine · 2024

DOI: 10.1371/journal.pmed.1004400 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS Medicine, 2024. Verfasst von Floris Bosch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Tergooi Hospitals, Hilversum, the Netherlands. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Neoplasms, Atrial Fibrillation, Dabigatran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preclinical animal studies have suggested that myeloid cell–synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing whether patients with atrial fibrillation taking direct factor Xa inhibitors have lower risk of cancer and cancer-related mortality than patients taking the direct thrombin inhibitor dabigatran. Methods and findings This nationwide population-based cohort study in Denmark included adult patients with atrial fibrillation and without a history of cancer, who started taking a factor Xa inhibitor or dabigatran between 2011 and 2015. Data on medical history, outcomes, and drug use were acquired through Danish healthcare registries. The primary outcome was any cancer. Secondary outcomes were cancer-related mortality and all-cause mortality. Outcome events were assessed during 5 years of follow-up in an intention-to-treat analysis. The propensity score-based inverse probability of treatment weighting was used to compute cumulative incidence and subdistribution hazard ratios (SHRs) and corresponding 95% confidence intervals (CIs), with death as a competing event. Propensity scores were estimated using logistic regression and including in the model sex, age group at index date, comorbidities, and use of comedications. A total of 11,742 patients with atrial fibrillation starting a factor Xa inhibitor and 11,970 patients starting dabigatran were included. Mean age was 75.2 years (standard deviation [SD] 11.2) in the factor Xa cohort and 71.7 years (SD 11.1) in the dabigatran cohort. On the basis of the propensity score-weighted models, after 5 years of follow-up, no substantial difference in the cumulative incidence of cancer was observed between the factor Xa inhibitor (2,157/23,711; 9.11%, 95% CI [8.61%,9.63%]) and dabigatran (2,294/23,715; 9.68%, 95% CI [9.14%,10.25%]) groups (SHR 0.94, 95% CI [0.89,1.00], P value 0.0357). We observed no difference in cancer-related mortality (factor Xa inhibitors cohort 1,028/23,711; 4.33%, 95% CI [4.02%,4.68%]. Dabigatran cohort 1,001/23,715; 4.22%, 95% CI [3.83%,4.66%]; SHR 1.03, 95% CI [0.94,1.12]), but all-cause mortality was higher in the factor Xa inhibitor cohort (factor Xa inhibitors cohort 7,416/23,711; 31.31%, 95% CI [30.37%,32.29%]. Dabigatran cohort 6,531/23,715; 27.56%, 95% CI [26.69%,28.45%]; HR 1.17, 95% CI [1.13,1.21]). The main limitations of the study were the possibility of residual confounding and the short follow-up period.

Conclusions

In this population based cohort study, factor Xa inhibitor use was not associated with an overall lower incidence of cancer or cancer-related mortality when compared to dabigatran. We did observe an increase in all-cause mortality in the factor Xa inhibitor cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsNeoplasmsAtrial FibrillationDabigatranHumansDenmarkMaleFemaleAgedMiddle AgedAged, 80 and overCohort StudiesRegistriesRivaroxabanRisk FactorsIncidenceAntithrombins

Substanzen

Factor Xa InhibitorsDabigatranRivaroxabanAntithrombins

Autor:innen und Institutionen

  • Department of Internal Medicine, Tergooi Hospitals, Hilversum, the Netherlands.
  • Amsterdam UMC location University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands.
  • Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, the Netherlands.
  • Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Floris Bosch, Erzsébet Horváth-Puhó, Suzanne C Cannegieter, Nick van Es, Henrik T Sørensen

Zitieren

APA

Bosch, F., Horváth-Puhó, E., Cannegieter, S. C., van Es, N., & Sørensen, H. T. (2024). Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004400

Vancouver

Bosch F, Horváth-Puhó E, Cannegieter SC, van Es N, Sørensen HT. Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004400

BibTeX
@article{Bosch2024,
  author = {Bosch, Floris and Horváth-Puhó, Erzsébet and Cannegieter, Suzanne C and van Es, Nick and Sørensen, Henrik T},
  title = {Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study},
  journal = {PLOS Medicine},
  year = {2024},
  doi = {10.1371/journal.pmed.1004400}
}
Kostenlos starten →